Strategic Planning & Communication Flashcards

A regulatory affairs team is preparing a risk-based submission strategy for a novel medical device. Which factor MOST influences the choice between a 510(k) and a PMA pathway?

Answer: The level of risk the device poses to patients

The FDA classification system and associated submission pathway (510(k) vs. PMA) are primarily determined by the risk level of the device to patients.

Which communication approach is MOST effective when a regulatory agency issues a deficiency letter requesting additional clinical data?

Answer: Acknowledge receipt, request a meeting to clarify scope, and provide a detailed response plan with timelines

Acknowledging receipt, seeking clarification, and providing a structured response plan demonstrates professionalism and helps avoid misunderstandings with the agency.

When developing a global regulatory strategy for a pharmaceutical product, which of the following BEST describes a rolling submission approach?

Answer: Submitting completed dossier sections to the agency as they become available rather than waiting for the full dossier

A rolling submission allows sponsors to submit completed sections of a marketing application progressively, often used to expedite review for promising therapies.

A company's regulatory team must brief senior leadership on a complex FDA response. What is the MOST important principle when communicating technical regulatory information to non-expert executives?

Answer: Translate technical findings into business impact language with clear action items

Effective communication to executives requires framing regulatory information in terms of business risk, timelines, and required decisions rather than technical detail.

Which regulatory strategy tool is MOST useful for systematically mapping global market entry requirements across multiple regions?

Answer: Regulatory intelligence matrix

A regulatory intelligence matrix organizes country-specific requirements, timelines, and submission formats, enabling strategic comparison across target markets.

Under FDA's IND regulations, a sponsor must notify the agency and place a clinical hold if which situation arises?

Answer: An unexpected serious adverse event suggests an unreasonable risk to subjects

An unexpected serious adverse event (SUSAR) that suggests unreasonable risk to subjects triggers a clinical hold obligation under 21 CFR 312.

When aligning cross-functional teams on a regulatory submission timeline, which planning technique BEST identifies tasks that could delay the overall project if not completed on time?

Answer: Critical path analysis

Critical path analysis identifies the sequence of dependent tasks that determines the minimum project duration and highlights tasks where any delay impacts the final deadline.